Announcements

01APR

Removal of Component(s) - ONCE

LifeSci Biotechnology Products Index Removal of Component(s) – ONCE 4/1/2019 Effective at the market close on Wednesday, April 3, 2019, ONCE will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On 2/25/2019, Spark Therapeutics (ONCE) announced that it will be acquired by Roche AG for $114.50 per share in cash. 
13DEC

Index Semi-Annual Reconstitution (Final) - December 2018

The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Monday, December 17, 2018.  All positions will be equally-weighted, with weights determined as of the closing prices on Thursday, December 13, 2018.   LifeSci Biotechnology Clinical Trials Index Additions (23 stocks): -          ALLK, AMRS, APTX, ASND, ASRT, AUTL, AVRO, CRNX, DRNA, EIDX, KDMN, KNSA, MRKR, NITE, OPTN, PRNB, PRQR, RARX, STIM, SVRA, TCDA, UBX, WVE Deletions (26 stocks): -          ADRO, ADVM, AKAO, ALBO, ALNY, ARRY, AVEO, AXON, BLCM, CBIO, CLSD, ECYT, FOLD, IDRA, LOXO, MLNT, MNOV, MRNS, PIRS, PRTK, RCUS, SELB, SGYP, SYRS, TORC, VSTM Summary: -         
10DEC

Index Semi-Annual Reconstitution (Preliminary) - December 2018

The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Monday, December 17, 2018.  All positions will be equally-weighted, with weights determined as of the closing prices on Thursday, December 13, 2018.  The preliminary changes, subject to modification, are summarized below. LifeSci Biotechnology Clinical Trials Index Additions (24 stocks):  ALLK, AMRS, APTX, ASND, ASRT, AUTL, AVRO, CRNX, DRNA, EIDX, KDMN, KNSA, MRKR, NITE, OPTN, PRNB, PRQR, RARX, STIM, SVRA, TCDA, TOCA, UBX, WVE Deletions (26 stocks):  ADRO, ADVM, AKAO, ALBO, ALNY, ARRY, AVEO, AXON, BLCM, CBIO, CLSD, ECYT, FOLD, IDRA, LOXO, MLNT,
14JUN

LifeSci Biotechnology Indexes: Semi-Annual Reconstitution (Final)

The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Monday, June 18, 2018.  All positions will be equally-weighted, with weights determined as of the closing prices on Thursday, June 14, 2018.  (There are no changes to the preliminary index changes announced on June 8, 2018.) LifeSci Biotechnology Clinical Trials Index Additions (27 stocks): ADAP, ADVM, ALBO, APLS, ARQL, ARWR, BHVN, CBIO, CCXI, CLSD, DCPH, DNLI, ECYT, FATE, MNOV, PGNX, RCKT, RCUS, RYTM, SELB, SGYP, SLDB, SRNE, SYRS, TORC, VKTX, VSTM Deletions (11 stocks): AGIO, ARDX, CALA, CLDX, DOVA, JNCE, MCRB, NLNK, RARE, RIGL,
08JUN

LifeSci Biotechnology Index Semi-Annual Reconstitution (Preliminary)

The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Monday, June 18, 2018.  All positions will be equally-weighted, with weights determined as of the closing prices on Thursday, June 14, 2018.  The preliminary changes, subject to modification, are summarized below. LifeSci Biotechnology Clinical Trials Index Additions (27 stocks): ADAP, ADVM, ALBO, APLS, ARQL, ARWR, BHVN, CBIO, CCXI, CLSD, DCPH, DNLI, ECYT, FATE, MNOV, PGNX, RCKT, RCUS, RYTM, SELB, SGYP, SLDB, SRNE, SYRS, TORC, VKTX, VSTM Deletions (11 stocks): AGIO, ARDX, CALA, CLDX, DOVA, JNCE, MCRB, NLNK, RARE, RIGL, TTPH Summary: The updated index will have 98
09MAY

Removal of Component(s) - AVXS

LifeSci Biotechnology Clinical Trials Index Removal of Component(s) – AVXS 5/9/2018 Effective at the market close on Monday, May 14, 2018, AVXS will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On 4/9/2018, AveXis (AVXS) announced that it will be acquired by Novartis AG for $218 per share in cash. 
06FEB

Removal of Component(s) - RXDX, JUNO, BIVV

LifeSci Biotechnology Clinical Trials Index LifeSci Biotechnoloogy Products Index Removal of Component(s) – RXDX, JUNO, BIVV 2/6/2018   Effective at the market close on Thursday, February 8, 2018, RXDX and JUNO will be removed from the LifeSci Biotechnology Clinical Trials Index and their combined values will be redistributed to the remaining index components based on their weights. On 12/22/2017, Ignyta (RXDX) announced that it will be acquired by Roche for $27 per share in cash.  On 1/22/2018, Juno Therapeutics (JUNO) announced that it will be acquired by Celgene for $87 per share in cash.  Effective at the market close on Thursday, February 8, 2018, BIVV will be removed
14DEC

LifeSci Biotechnology Index Semi-Annual Reconstitution

The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Monday, December 18, 2017.  All positions will be equally-weighted, with weights determined as of the closing prices on Thursday, December 14, 2017.  
30AUG

Virtus ETF Solutions Rebrands BioShares ETFs; Moves Listings for BBC, BBP to NYSE Arca

Virtus ETF Solutions Rebrands BioShares ETFs; Moves Listings for BBC, BBP to NYSE Arca NEW YORK, Aug. 30, 2017 /PRNewswire/ -- Virtus ETF Solutions, an affiliate of Virtus Investment Partners, Inc. (NASDAQ:VRTS) and multi-manager ETF sponsor, today announced that effective September 1, 2017, the BioShares Biotechnology Clinical Trials Fund (Ticker: BBC) and the BioShares Biotechnology Products Fund (Ticker: BBP) will change their names to the Virtus LifeSci Biotech Clinical Trials ETF and the Virtus LifeSci Biotech Products ETF, respectively, and will change their primary listing venue to NYSE Arca. The funds, which are advised by Virtus ETF Advisers, will retain their current ticker symbols when they
16JUN

BioShares Biotechnology ETFs Complete Semi-Annual Rebalance and Recomposition

New York, June 16, 2017 — LifeSci Index Partners, LLC, an affiliate company of LifeSci Advisors, and a New York City-based investment advisor and index provider, today announced the completion of its semi-annual rebalancing and recomposition for its BioShares Biotechnology exchange-traded funds (ETFs), which trade under the symbols BBC and BBP on Nasdaq. These passively-managed funds are designed to track their respective, rules-based indexes. 
16DEC

BioShares Biotechnology ETFs Complete Semi-Annual Rebalance and Recomposition

New York, December 16, 2016 — LifeSci Index Partners, LLC (“LSIP”), a New York City-based investment advisor and index provider, today announced the completion of its semi-annual rebalancing and recomposition for its BioShares Biotechnology exchange-traded funds (ETFs), which trade under the symbols BBC and BBP on Nasdaq. These passively-managed funds are designed to track their respective, rules-based indexes. 
16JUN

BioShares Biotechnology ETFs Complete Semi-Annual Rebalance and Recomposition

The BioShares Biotechnology Funds are the only ETFs to separate Clinical Trials stage companies and Products stage companies into two distinct funds. The BioShares Biotechnology Clinical Trial Fund (BBC) and BioShares Biotechnology Product Fund (BBP) offer investors exposure to these two distinct segments of the biotechnology sector while diversifying some of the risks associated with any single company.